Status:
RECRUITING
The Benefits of Continued Use of Ovarian Function Suppression After 5 Years
Lead Sponsor:
Hongmei Zheng, PhD
Conditions:
Breast Cancer Female
Endocrine Therapy
Eligibility:
FEMALE
18-60 years
Brief Summary
To observe and evaluate the clinical efficacy and safety of continuous use of OFS for premenopausal patients with early breast cancer after 5 years use of OFS. This study is a multicenter, prospectiv...
Eligibility Criteria
Inclusion
- Diagnosed with early primary breast cancer
- Female aged 18-60 years (including 18 year and 60 year)
- Hormone receptor (HR) positive HER2 negative
- Receive 5 years of OFS treatment
- ECOG score 0-1
- Voluntarily join this study and sign the informed consent form;
- The researcher believes that it can benefit.
Exclusion
- The patient is receiving treatment that affects OFS at the same time The patient has received OFS treatment for less than 5 years
- Central nervous system metastases with known obvious symptoms, such as headache, cerebral edema, blurred vision
- Invasive metastases with known obvious symptoms
- Invasive metastases with known obvious symptoms
- Doctors think it is not suitable for inclusion
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2028
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06050109
Start Date
September 1 2023
End Date
September 1 2028
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wu Xinhong
Wuhan, Hubei, China